Volt Lithium Announces Executive Team Appointment, AGM and Proposed Strategic Name Change, Prepares for Future U.S. Transition
CALGARY, Alberta, May 27, 2025 (GLOBE NEWSWIRE) -- Volt Lithium Corp. (TSXV: VLT | OTCQB: VLTLF | FSE: I2D) ('Volt' or the 'Company') is pleased to announce that Marty Scase, Volt's co-founder and Board member, has agreed to join the Volt management team as Executive Chairman. This leadership enhancement, combined with recent operational milestones, supports the Company's strategy to expand growth and commercial opportunities within the U.S. critical minerals sector. Volt also announces details of its upcoming annual and special meeting ('AGM'), including a proposal for a strategic name change and continued corporate focus on corporate presence and operations within the United States. These initiatives reflect the Company's ongoing strategic alignment with U.S. policies supporting U.S. domestic critical mineral production.
Annual and Special Meeting Details
Date: June 18, 2025
Time: 12:00 p.m. (MDT)
Location: Suite 1925, 639 – 5th Avenue SW, Calgary, Alberta T2P 0M9
The AGM agenda will include a proposal to change the Company's name to LibertyStream Infrastructure Partners Inc. Full meeting details, including director elections, auditor appointments, and incentive plan approvals, are provided in the Management Information Circular available on SEDAR+ (www.sedarplus.ca) and the Company's website.
Management Appointment
Volt is pleased to announce that Volt co-founder, co-inventor of Volt's extraction technology, and member of the Board, Marty Scase, has agreed to join the management team as Executive Chairman. Mr. Scase's transition to Executive Chairman reflects his increased daily involvement in advancing the Company's extraction technologies as Volt moves toward commercial production. As the Company continues its rapid growth path in the U.S., Mr. Scase will continue to drive Volt's overall strategy for innovation and technology development as it transitions to commercial operations.
'Alex and I started Volt with the goal of efficiently extracting lithium from oilfield brines,' commented Marty Scase. 'With the new LibertyStream name reflecting our broader ambition, I'm excited to deepen my involvement and support the team as we further develop our extraction capabilities and explore additional opportunities from the resources we process.'
'I'm very pleased Marty is joining the management team,' commented Alex Wylie, Volt's President and CEO. 'His commitment and experience have always been central to our technology's development. Marty stepping into this expanded role, alongside our new name, highlights our intent to broaden the applications of the infrastructure we are integrating in field operations.'
Corporate Update and Strategic Rationale
Following the commissioning of its Field Simulation Centre in Calgary in late 2023, Volt established collaborations with U.S. oil and gas operators, validating the effectiveness of its lithium extraction technology.
In May 2024, a partnership and investment from a Permian Basin operator facilitated the deployment of Volt's initial Generation 1 Field Unit in Texas. In September 2024, the Generation 1 unit was deployed and began processing 600 barrels of oil field brine per day. Subsequently, in January and February 2025, Volt successfully installed and began operating its Generation 5 Field Unit, which can now process over 10,000 barrels of oilfield brine per day.
Since its installation, Volt has completed over 300 test runs with the Generation 5 Unit, effectively identifying optimal operating parameters to support economically viable commercial-scale lithium production, even at relatively low lithium concentration levels in the brine.
Additionally, as previously referred to in Volt News Release dated December 10, 2024, Volt, in partnership with Wellspring Hydro, secured supportive governmental backing, including a U.S. $2.5 million grant from the State of North Dakota, underscoring alignment with U.S. critical mineral production initiatives.
With these U.S. partnerships, Volt's Generation 5 Field Unit now represents the largest known operational Direct Lithium Extraction (DLE) system processing oilfield brines in North America. The modular design of the system is specifically intended for efficient and cost-effective scalability, offering the potential to quickly respond to growing domestic demand.
Strategic U.S. Corporate Transition and Name Change
Building upon progress made through U.S. partnerships, Volt seeks shareholder approval to rename the company LibertyStream Infrastructure Partners Inc. The proposed name, LibertyStream Infrastructure Partners Inc., reflects the Company's strategic evolution toward becoming an essential infrastructure partner for the U.S. oil and gas industry, focused on unlocking domestic critical mineral resources and engaging effectively with U.S. domestic customers to support supply chain security.
Leverage participation in U.S. federal programs designed to strengthen domestic critical mineral production.
Align operations closely with U.S. strategic initiatives emphasizing innovation, domestic mineral production, and supply-chain resilience.
Volt's intended future transition to business primarily in the U.S. strategically positions the Company to align with favorable governmental policies and initiatives designed to enhance critical mineral supply.
Looking Ahead
With these foundational elements in place—proven technology, North America's largest operational DLE system processing oilfield brines, strategic U.S. partnerships, and a strengthened leadership team—Volt (to be LibertyStream Infrastructure Partners Inc. following shareholder approval in June 2025) is decisively advancing from demonstration to initial commercial-scale lithium production. Volt is now actively pursuing opportunities to meet the growing U.S. domestic demand for critical minerals and look forward to updating shareholders on our commercialization milestones. Further updates will be provided as additional commercialization milestones are achieved.
About Volt Lithium
Volt is a lithium development and technology company aiming to be one of North America's first commercial producers of lithium carbonates from oilfield brine. Our strategy is to generate value for shareholders by leveraging management's hydrocarbon experience and existing infrastructure to extract lithium deposits from existing wells, thereby reducing capital costs, lowering risks and supporting the world's clean energy transition. With four differentiating pillars, and a proprietary Direct Lithium Extraction ('DLE') technology and process, Volt's innovative approach to development is focused on generating the highest lithium recoveries with lowest costs, positioning us for future commercialization. We are committed to operating efficiently and with transparency across all areas of the business staying sharply focused on creating long-term, sustainable shareholder value. Investors and/or other interested parties may sign up for updates about the Company's continued progress on its website: https://voltlithium.com/.
Contact Information
For Investor Relations inquiries or further information, please contact:
Alex Wylie, President & CEOT: +1.403.830.5811E: info@voltlithium.com
Or
Bill McClain, Investor RelationsT: +1.604.773.9423E: info@voltlithium.com
Forward Looking Statements
This news release includes certain 'forward-looking statements' and 'forward-looking information' within the meaning of applicable Canadian securities laws. When used in this news release, the words 'anticipate', 'believe', 'estimate', 'expect', 'target', 'plan', 'forecast', 'may', 'will', 'would', 'could', 'schedule' and similar words or expressions, identify forward-looking statements or information. Statements, other than statements of historical fact, may constitute forward-looking information and include, without limitation, information with respect to the Company's anticipated operational milestones, the anticipated name change of the Company and transition to operations predominantly in the United States, the deployment of the Field Unit in the Permian Basin, the production of battery grade lithium by the Field Unit, and the commercial production of lithium from oilfield brine. With respect to the forward-looking information contained in this press release, the Company has made numerous assumptions. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies and may prove to be incorrect. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein including those known risk factors outlined in the Company's annual information form for the year ended June 30, 2024 and (final) short form base shelf prospectus dated July 20, 2023. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Oasis Intends to Vote Against Kyocera's Top Management at the Upcoming AGM
*Kyocera has been facing chronic underperformance, with its stock price remaining depressed over the long-term and profitability continuing to deteriorate sharply *Although Kyocera has announced certain management reform initiatives, they fall far short of the necessary fundamental changes needed to transform the Company *On May 14, Oasis released a "Seven-Point Plan" calling for more substantive reforms at Kyocera, including the acceleration of non-core business divestitures and improvements to the Company's inefficient capital structure *However, Kyocera has so far failed to address the "Seven Point Plan" and has demonstrated little commitment to genuine transformation *In its latest results, Kyocera achieved an ROE of just 0.8% *Oasis will vote against the reappointment of Chairman Yamaguchi and President Tanimoto at the upcoming AGM, holding them accountable for the underperformance and poor capital allocation *Both ISS and Glass Lewis have recommended to vote against the reappointment of Kyocera Chairman Yamaguchi, and ISS additionally recommends voting against President Tanimoto More information available at HONG KONG, June 11, 2025--(BUSINESS WIRE)--Oasis Management Company Ltd. ("Oasis") is manager to funds that beneficially own shares in Kyocera Corporation (6971 JP) ("Kyocera" or the "Company"). Oasis has adopted the Japan FSA's "Principles of Responsible Institutional Investors" (a.k.a. the Japan Stewardship Code) and in line with those principles, Oasis monitors and engages with its investee companies. At its May 14, 2025 earnings call, Kyocera reported on the progress of its management reforms. The Company appeared to acknowledge its past mistakes and expressed an intention to take the first step toward change. Specifically, Kyocera recognized the inefficiencies caused by the dispersal of management resources due to diversification and announced its policy to restructure its business portfolio in order to focus on its core strengths. However, like many shareholders and market participants, Oasis remains highly skeptical of Kyocera's commitment and ability to execute meaningful change especially in light of its modest plans and continued commitment to manufacturing solar panels and telecommunication devices. Moreover, underperformance against its management targets has become the norm. Since the fiscal year ended March 2020, Kyocera has exceeded its operating profit targets only once. This track record raises serious concerns about the current management team's ability to formulate and execute plans, casting significant doubt on whether they can even implement the current, modest reform plan. The latest earnings briefing further highlighted weak progress. Although Kyocera announced plans to exit JPY200 billion worth of non-core businesses, only JPY7.3 billion has been announced so far. This year's forecast includes just a JPY10 billion revenue reduction from exits. Kyocera's capital policy also remains insufficient. Although the Company has announced "Future Reduction Plan" to lower cross-shareholdings to below 20% of net assets, it has yet to provide a clear timeline for achieving this goal. Shareholders' dissatisfaction is growing. Approval for the Company's president at the AGM has dropped from 96% in 2015 to just 65% in 2023. ISS and Glass Lewis have once again recommended voting against the reappointment of Kyocera's Chairman, Mr. Yamaguchi. ISS has also recommended voting against President, Mr. Tanimoto, citing continued underperformance in ROE and capital misallocation. Oasis also believes that the top management is responsible for Kyocera's weak performance and therefore intends to vote against the reappointment of both individuals. Amid growing pressure from shareholders, Kyocera announced plans to reduce the cap on board directors from 20 to 12. At the same time, the Company also plans to increase the number of internal directors -- a move that runs against the broader efforts by many Japanese companies to strengthen board independence thereby decreasing the percentage of independent directors. In order for Kyocera to achieve genuine transformation and resolve its excessive diversification and inefficient capital structure, Oasis urges the full implementation of the following Seven-Point Plan: Divest non-core businesses amounting to over JPY660 billion of revenue. Exit the Organic Packages to prevent further losses. Restructure its KAVX subsidiary to achieve higher margins in line with peers. Stop losses by halting investment into GaN and millimeter-wave technologies which have little potential to produce material returns. Focus on its core business such as ceramics to capture untapped opportunities. Commit to aggressive M&A to reinforce core businesses. Announce a buyback program of JPY1 trillion over the next four years, amounting to approximately 37% of the Company. By implementing this plan, we believe that the stock could see an upside of over +100% from current levels. Seth Fischer, Founder & Chief Investment Officer of Oasis, said: "Kyocera's excessive diversification has long prevented it from realizing its full potential. The Company continues to support underperforming businesses while failing to prioritize investment and growth opportunities within its best businesses such as ceramics packaging, and the automotive and semiconductor sectors. With cross-shareholdings still accounting for 53% of its net assets and an ROE of just 0.8%, the time for meaningful change is now. Management needs to address the twin problems of over-diversification and over-capitalization of its balance sheet by exiting underperforming businesses, leaning into its best growth opportunities, and taking a much more ambitious stance on unwinding cross-shareholdings to improve returns on capital. Kyocera needs brave, large steps forward to achieve these goals. The current half measures are not enough." Full details can be viewed at All stakeholders are encouraged to contact Oasis at info@ *** Oasis Management Company Ltd. manages private investment funds focused on opportunities in a wide array of asset classes across countries and sectors. Oasis was founded in 2002 by Seth H. Fischer, who leads the firm as its Chief Investment Officer. More information about Oasis is available at Oasis has adopted the Japan FSA's "Principles for Responsible Institutional Investors" (a.k.a. the Japan Stewardship Code) and, in line with those principles, Oasis monitors and engages with our investee companies. The information and opinions contained in this press release (referred to as the "Document") are provided by Oasis Management Company ("Oasis") for informational or reference purposes only. The Document is not intended to solicit or seek shareholders to, jointly with Oasis, acquire or transfer, or exercise any voting rights or other shareholder's rights with respect to any shares or other securities of a specific company which are subject to the disclosure requirements under the large shareholding disclosure rules under the Financial Instrument and Exchange Act. Shareholders that have an agreement to jointly exercise their voting rights are regarded as Joint Holders under the Japanese large shareholding disclosure rules and they must file notification of their aggregate shareholding with the relevant Japanese authority for public disclosure under the Financial Instruments and Exchange Act. Except in the event that Oasis expressly enters into the agreement as a joint holder requiring such disclosure, Oasis does not intend to take any action triggering reporting obligations as a Joint Holder. The Document exclusively represents the opinions, interpretations, and estimates of Oasis. View source version on Contacts Media Contact For all inquiries, please contact:Taylor Hallmedia@
Hamilton Spectator
an hour ago
- Hamilton Spectator
MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm,' the 'Company,' 'we' or 'us'), a pharmaceutical company specialized in precision-based cannabinoids, today reminded its shareholders that the deadline is approaching to cast your vote for the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the 'Meeting'). All votes must be received no later than 3:00 p.m. (Eastern time) on Friday, June 13, 2025. We encourage shareholders to please vote using ONLY the GREEN proxy or GREEN voting instruction card and to support each of the director nominees recommended by MediPharm's Board of Directors (the 'Board') and the other matters being considered at the Meeting. To ensure your proxy is counted at the Meeting, please submit it well in advance of the June 13 proxy cut-off. Please remember that your vote is important, regardless of the number of shares you own. MediPharm's Strategy Is Working MediPharm has undergone a successful transformation over the past three years, led by David Pidduck who joined as CEO in April 2022. Faced with negative gross margins and an operating loss of $48.9 million in 2021, the Company implemented a plan to refocus operations, prioritizing the most strategic business lines, divesting of non-core assets and reducing operating costs. The acquisition of VIVO Cannabis Inc. in April 2023 provided a foundation to accelerate international growth and realize synergies from combining the two companies. We described our strategic turnaround in a Chair's Letter to Shareholders dated May 11, 2025 . In Q1 2025, we continued our track record of year-over-year revenue growth, led by an 87% revenue increase in the international medical market which now represents more than half our revenue. We achieved positive Adjusted EBITDA1 for the first time in more than five years and our gross profit margin of 38.7% was the highest in more than five years. Operating loss narrowed to less than $0.5 million, an improvement of more than $3 million from Q1 2024. A strong cash position with virtually no debt enabled us to invest in inventory to pursue near-term growth opportunities. With diversification in our product mix and sales channels, a strong reputation as a GMP-certified producer and expanding international partnerships, MediPharm has established a solid foundation for further growth. We are confident the strategy and team currently in place is the best way to create sustainable value. The Dissident Group has NOT Made a Case for Change Apollo Technology Capital Corp. ('Apollo'), led by Chairman and CEO Regan McGee, and former MediPharm CEO and director Patrick McCutcheon (collectively, the 'Concerned Stakeholder'), have filed an amended and restated dissident proxy circular dated May 15, 2025, as updated by an addendum dated June 4, 2025, nominating six alternative directors (the 'Dissident Nominees') for the Board. In recent weeks we have described numerous deficiencies in Apollo's plan and the track record of Mr. McGee and the other Dissident Nominees. With the addition of Pat McCutcheon to the dissident team, a number of new concerns now emerge. Important points for shareholders to remember include the following. Patrick McCutcheon's Tenure at MediPharm Mr. McCutcheon, who is now formally acknowledged as a member of the Concerned Stakeholder dissident group, served as CEO of MediPharm until December 10, 2020, Chairman of the Board until August 16, 2021, and as a director until December 7, 2021. While Apollo has been critical of the current leadership team's performance on such measures as share price, revenue growth, gross profit, cash usage and operating loss, we note the following about Mr. McCutcheon's track record with the Company. The Board urges shareholders to send Mr. McGee and Mr. McCutcheon a strong message that you want to stop their expensive and aggressive attacks against your Company. Vote for the Highly Qualified MediPharm Nominees MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions. To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting . You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Shareholder Voting Assistance: If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at: North American Toll-Free Number: 1.888.777.2059 Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075 Email: assistance@ North American Toll-Free Facsimile: 1.877.218.5372 For up-to-date information and assistance in voting please visit: Investor Contact: MediPharm Labs Investor Relations Telephone: +1 416.913.7425 Email: investors@ Media Contact: John Vincic Oakstrom Advisors +1 (647) 402-6375 john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, the ability of the Company to pursue near-term growth opportunities, future growth opportunities available to the Company, sustainable value creation at MediPharm, any impacts to MediPharm shareholders of the actions relating to the Dissident Nominees described herein, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change. ___________________________________ 1 Represents a non-GAAP financial measure, which is not a standardized financial measure under IFRS and which might not be comparable to similar financial measures disclosed by other issuers. MediPharm calculates Adjusted EBITDA as net income (loss) with interest, taxes, depreciation and amortization, non-cash adjustments and other unusual or non-recurring items added back. Refer to the sections entitled 'Use of Non-IFRS Financial Measures' and 'Reconciliation of Non-IFRS Measures' in MediPharm's management's discussion and analysis for the three months ended March 31, 2025, which is incorporated by reference herein and which can be located on MediPharm's profile on SEDAR+ at .
Yahoo
an hour ago
- Yahoo
BuildDirect Retains Market-Making Services
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - Technologies Inc. (TSXV: BILD) ("BuildDirect" or the "Company") a leading omnichannel building material retailer, today announced that the Company, subject to regulatory approval, retained Venture Liquidity Providers Inc. ("VLP") to execute its market-making service to provide assistance in maintaining an orderly trading market for the common shares of the Company. The market-making service will be undertaken by VLP through a registered broker, W.D. Latimer Co. Ltd., in compliance with the applicable policies of the TSX Venture Exchange and other applicable laws. For its services, the Company has agreed to pay VLP CAD$5,000 per month. The agreement may be terminated at any time by the Company or VLP. The Company and VLP act at arm's length, and VLP has no present interest, directly or indirectly, in the Company or its securities. The finances and the shares required for the market-making service are provided by W.D. Latimer. The fee paid by the Company to VLP is for services only. VLP is a specialized consulting firm based in Toronto providing a variety of services focused on TSXV-listed issuers. About BuildDirect BuildDirect (TSXV: BILD) is an expanding omnichannel building materials retailer, specializing in Pro Centers-strategic distribution hubs designed to serve professional contractors and trades. The Company is actively scaling its footprint through a combination of organic growth and strategic acquisitions, driving efficiency and market expansion. For more information, visit Forward-Looking Information: This press release contains statements which constitute "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"), including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking statements are often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions. These statements reflect management's current beliefs and expectations and are based on information currently available to management as at the date hereof. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. Among those factors are changes in consumer spending, availability of mortgage financing and consumer credit, changes in the housing market, changes in trade policies, tariffs or other applicable laws and regulations both locally and in foreign jurisdictions, availability and cost of goods from suppliers, fuel prices and other energy costs, interest rate and currency fluctuations and changes in general economic, business and political conditions. These forward-looking statements may be affected by risks and uncertainties in the business of the Company and general market conditions. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release reflect the Company's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. There may be other risks, uncertainties and factors that cause results not to be as anticipated, estimated or intended and such changes could be material. These forward-looking statements are made as of the date of this press release, and BuildDirect assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information: Shawn Wilson, CEOshawnwilson@ BuildDirect Investor Relationsir@ To view the source version of this press release, please visit Sign in to access your portfolio
